Press Releases

We’re Delivering the Promise of Healthier Lives.

CURE PHARMACEUTICAL 

Press Releases

We specialize in optimal formulations to achieve targeted release and exposure of medications.​

CURE Pharmaceutical Licenses Cannabis Extraction Patents to Vanguard Scientific

CURE Pharmaceutical Licenses Cannabis Extraction Patents to Vanguard Scientific

Vanguard Scientific builds customer trust with CUREinside™ patented methods LOS ANGELES – February 12, 2020 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced a licensing and collaboration agreement with Vanguard Scientific Systems, Inc., a premier provider of equipment, systems and performance solutions servicing the botanical extraction industry, including both […]

read more
CURE Pharmaceutical Expands to Europe, Signs Licensing Agreement with ReLeaf Europe to Provide Advanced Cannabinoid Delivery

CURE Pharmaceutical Expands to Europe, Signs Licensing Agreement with ReLeaf Europe to Provide Advanced Cannabinoid Delivery

CURE debuts “CUREinside” quality mark on the packaging of ReLeaf Europe’s sublingual tinctures and new topical cream product lines  Oxnard, Calif. February 5, 2020 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, announced today that it has signed an exclusive licensing agreement with ReLeaf Europe, one of Europe’s leading pharmaceutical groups […]

read more
CURE Pharmaceutical Takes First Step to Acquire Coeptis Pharmaceuticals and its Combination Drug for Osteoarthritis Pain and Hypertension

CURE Pharmaceutical Takes First Step to Acquire Coeptis Pharmaceuticals and its Combination Drug for Osteoarthritis Pain and Hypertension

OXNARD, Calif., November 14, 2019 – CURE Pharmaceutical (OTC: CURR) (“CURE”), an innovative drug delivery and development company, today announced that it purchased a $200,000 convertible promissory note issued by Coeptis Pharmaceuticals, Inc., a biopharmaceutical company engaged in the acquisition, development and commercialization of branded 505(b)(2) pharmaceutical products. This note represents an initial step toward […]

read more
CURE Pharmaceutical Debuts CUREform Drug Delivery Line Adding Chewables and Emulsions

CURE Pharmaceutical Debuts CUREform Drug Delivery Line Adding Chewables and Emulsions

Alternative dosage demand drives company’s manufacturing expansion OXNARD, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, announces the expansion of its oral drug delivery product line creating CUREform™ which includes CUREfilm®, one of the most advanced oral thin films on the market today. The new line adds […]

read more
CURE Pharmaceutical Promotes Dr. Vered Gigi to Chief Scientific Officer

CURE Pharmaceutical Promotes Dr. Vered Gigi to Chief Scientific Officer

Biopharma star brings extensive translational research experience as company advances its clinical indications Oxnard, Calif. – October 1, 2019 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, has appointed Dr. Vered Gigi as its Chief Scientific Officer. In this role, Dr. Gigi will oversee all CURE’s research and development. Dr. Gigi […]

read more
CURE Pharmaceutical Takes First Step To Secure Hemp CBD Supply Chain by Partnering with Fytiko Farms

CURE Pharmaceutical Takes First Step To Secure Hemp CBD Supply Chain by Partnering with Fytiko Farms

OXNARD, Calif. – August 21, 2019 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has signed a deal with Oklahoma-based hemp grower Fytiko Farms. The deal gives CURE direct, guaranteed access to high-quality plant material for exclusive use in its proprietary oral thin film (OTF) drug delivery system, […]

read more
CURE Pharmaceutical Expands Board with Two Women Directors

CURE Pharmaceutical Expands Board with Two Women Directors

Oxnard, Calif. – August 7, 2019 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced the addition of two directors to its Board, Dr. Lauren Chung, Ph.D. and Mrs. Anya Goldin. Dr. Chung has experience in healthcare investments and academic accomplishments in scientific fields and Goldin brings expertise in both […]

read more
CURE Pharmaceutical Secures Patent on High Loading of Active Ingredient in Oral Thin Films

CURE Pharmaceutical Secures Patent on High Loading of Active Ingredient in Oral Thin Films

OXNARD, Calif. – July 24, 2019 – CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No. 13/890,875. The new patent builds on one of CURE’s key technology differentiators – loading higher amounts of drug active on an oral thin film (OTF) using its proprietary drug delivery […]

read more
CURE Pharmaceutical Secures Patent on Oral Thin Films With Bi-Phasic Release of Natural Ingredients

CURE Pharmaceutical Secures Patent on Oral Thin Films With Bi-Phasic Release of Natural Ingredients

OXNARD, Calif. – July 16, 2019 – CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No. 15/666,057, which covers edible thin films with natural active ingredients located in both a powder coating and the film matrix for a bi-phasic release profile. “With an increased consumer demand […]

read more

CURE Pharmaceutical and Canopy Growth To Produce CBD Oral Thin Films 

OXNARD, Calif. – June 19, 2019 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it is collaborating with Canopy Growth Corporation (TSX: WEED) (NYSE: CGC), (“Canopy”) to develop a new low-dose cannabidiol (CBD) oral thin film (OTF) using CURE’s patented CUREfilm™ technology for global distribution. This CUREfilm license gives […]

read more
CURE Pharmaceutical to Present at the 9th Annual LD Micro Invitational

CURE Pharmaceutical to Present at the 9th Annual LD Micro Invitational

LOS ANGELES, May 30, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that it will be presenting at the 9th Annual LD Micro Invitational on Wednesday, June 5th at 11:40 a.m. PT at the Luxe Sunset Boulevard Hotel in Los Angeles. The conference will be held on June 4-5, 2019. […]

read more
CURE Pharmaceutical Secures Patent on Oral Thin Film Containing Bioactive Cannabinoid Molecules

CURE Pharmaceutical Secures Patent on Oral Thin Film Containing Bioactive Cannabinoid Molecules

OXNARD, Calif. – May 22, 2019 – CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced the issuance of U.S. Patent No. 10,307,397, which covers the high load of bioactive cannabinoid molecules integrated into oral thin film dosage forms. The cannabinoids include cannabidiol (CBD) and tetrahydrocannabinol (THC). “Advances in drug delivery are […]

read more
CURE Pharmaceutical Closes Acquisition Of Privately-Held Chemistry Holdings Inc.

CURE Pharmaceutical Closes Acquisition Of Privately-Held Chemistry Holdings Inc.

Acquired Technology Expands Core CUREfilm™ Platform and Strengthens Balance Sheet OXNARD, Calif., May 14, 2019 (GLOBE NEWSWIRE) — Cure Pharmaceutical (OTC: CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has closed on the previously announced acquisition of Chemistry Holdings Inc. (“Chemistry Holdings”, “CH”), a formulation technology company that is developing innovative […]

read more
Meroven LLC and CURE Pharmaceutical Enter Exclusive Marketing and Distribution Agreement for Spee-D for the USA

Meroven LLC and CURE Pharmaceutical Enter Exclusive Marketing and Distribution Agreement for Spee-D for the USA

CHICAGO – May 2, 2019 – Today, at the CPhI Conference, Meroven LLC announced a five-year agreement with CURE Pharmaceutical Corporation (OTCQB: CURR) to exclusively market and distribute Spee-D®, a weekly dose oral thin film Vitamin D3 in the USA. Under the terms of the agreement, Meroven LLC will be responsible for conducting all regulatory […]

read more
CURE Pharmaceutical Extends Closing Of Privately-Held Chemistry Holdings Inc. Acquisition to May 13

CURE Pharmaceutical Extends Closing Of Privately-Held Chemistry Holdings Inc. Acquisition to May 13

OXNARD, Calif., May 01, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has extended the close of the previously announced acquisition of Chemistry Holdings Inc. (“Chemistry Holdings”, “CH”) to May 13, 2019. This merger transaction with Chemistry Holdings, a formulation technology company that […]

read more
CURE Pharmaceutical to Present at the Planet Microcap Showcase 2019

CURE Pharmaceutical to Present at the Planet Microcap Showcase 2019

CURE CEO to discuss expanded product pipeline and company’s continued execution into cannabinoid market. LAS VEGAS – April 30, 2019 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that it will be presenting at the Planet MicroCap Showcase at 8:30 a.m. on Wednesday, May 1, 2019 and CEO Rob […]

read more

CURE Pharmaceutical Named “Innovative Business of the Year” By Oxnard Chamber of Commerce

OXNARD, Calif., April 26, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR) (“CURE”), an innovative drug delivery and development company, has been named 2019’s Innovative Business of the Year by Oxnard Chamber of Commerce in recognition to the company’s innovative thinking for various programs, employing pioneering technology and a dedication to improving the health of […]

read more
Uptick Newswire Hosts CURE Pharmaceutical on The Stock Day Podcast to Discuss Major Milestones and 2019 Goals

Uptick Newswire Hosts CURE Pharmaceutical on The Stock Day Podcast to Discuss Major Milestones and 2019 Goals

PHOENIX, AZ / ACCESSWIRE / April 16, 2019 / Uptick Newswire Stock Day Podcast welcomed CURE Pharmaceutical (OTCQB: CURR) (”the Company”), a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CEO Rob Davidson joined Stock Day host Everett Jolly. To […]

read more
United Smart Cities and Cure Pharmaceutical Launch Global Healthcare Awareness Initiative

United Smart Cities and Cure Pharmaceutical Launch Global Healthcare Awareness Initiative

LOS ANGELES, April 9, 2019 —CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced a global healthcare awareness initiative with United Smart Cities for the purpose of educating, informing and providing the next generation healthcare solutions to the world’s 7.3 billion citizens.Recognizing escalating healthcare costs, CURE and United Smart Cities will […]

read more
CURE Pharmaceutical to Acquire Privately-Held Chemistry Holdings Inc., Expanding Its Technology Platform in Oral Drug Delivery

CURE Pharmaceutical to Acquire Privately-Held Chemistry Holdings Inc., Expanding Its Technology Platform in Oral Drug Delivery

** For FREQUENTLY ASKED QUESTIONS regarding this announcement, please click here to read FAQs ** OXNARD, Calif., April 1, 2019 – CURE Pharmaceutical (OTC: CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has agreed to acquire Chemistry Holdings Inc. (“Chemistry Holdings”, “CH”), a formulation technology company that is developing innovative delivery […]

read more